The 50 references without contexts in paper К. Мukhin Yu., О. Pylaeva A., К. Мухин Ю., О. Пылаева А. (2018) “Современные подходы в лечении синдрома Леннокса–Гасто (обзор литературы) // Modern approaches in the treatment of Lennox–gastaut syndrome (a review of literature)” / spz:neicon:rjdn:y:2018:i:2:p:34-57

1
Am J Hum Genet 2014;95(4):360–70.
(check this in PDF content)
2
PMID: 25262651. DOI: 10.1016/j. ajhg.2014.08.013. 30. Ferlazzo E., Adjien C.K., Guerrini R. et al. Lennox–Gastaut syndrome with
(check this in PDF content)
3
DOI: 10.1111/j.1528-1167.2008.01944.x. 31. Gastaut H., Roger J., Soulayrol R. et al. Childhood epileptic encephalopathy with diffuse slow spike-waves (otherwise known as “petit mal variant”) or Lennox sy
(check this in PDF content)
4
PMID: 4959714. 32. Genton P., Dravet Ch. The Lennox– Gastaut syndrome. In: Comprehensive еpileptology. 2nd edn. Eds.: J. Engel, T.A. Pedley. Philadelphia: Lippincot
(check this in PDF content)
5
DOI: 10.1212/01. wnl.0000303813.95800.0d. 34. Glauser T.A., Levisohn P.M., Ritter F., Sachdeo R.C.
(check this in PDF content)
6
DOI: 10.1111/j.1528-1157.2000.tb01563.x. 35. Guerrini R., Marini C. Epileptic еncephalopathies. In: Epilepsy and еpileptic seizures. Eds.: S. Shorvon, R. Guerrini, M. Cook, S. Lh
(check this in PDF content)
7
University Press, 2013. Pр. 177–180. 36. Hancock E.C., Cross J.H. Treatment of Lennox–Gastaut syndrome. Cochrane
(check this in PDF content)
8
Database Syst Rev 2013;2:CD003277.
(check this in PDF content)
9
DOI: 10.1002/14651858.CD003277. 37. Holthausen H., Piper T., Winkler P. et al. Electro-clinical-pathological correlations in focal cortical dysplasia (FCD) at young ages. Childs Ne
(check this in PDF content)
10
Ther Adv Neurol Disord 2013;6(3): 189–98. PMID: 23634191.
(check this in PDF content)
11
DOI: 10.1177/1756285613481083. 39. Hughes J.R., Patil V.K. Long-term electroclinical changes in the Lennox–Gastaut syndrome before, during and after the sl
(check this in PDF content)
12
Syst Dis 2012;4:51–63. PMID: 23650467.
(check this in PDF content)
13
DOI: 10.4137/JCNSD.S5097. 41. Kerr M., Kluger G., Philip S. Evolution and management of Lennox–Gastaut syndrome through adolescence and into adulthood: are seizures always the
(check this in PDF content)
14
DOI: 10.1684/epd.2011.0409. 42. Kessler S.K., McCarthy A., Cnaan A., Dlugos D.J.
(check this in PDF content)
15
Epilepsy Res 2015;112:18–26.
(check this in PDF content)
16
PMID: 25847334. DOI: 10.1016/j. eplepsyres.2015.02.003. 43. Kim J.Y., Lee C.G., Yu H.J. et al. The efficacy and tolerability of rufinamide in intractable pediatric epilepsy.
(check this in PDF content)
17
DOI: 10.14581/jer.12009. 44. Kluger G., Haberlandt E., Kurlemann G. et al. First European long-term experience with the orphan drug rufinamide in child-
(check this in PDF content)
18
DOI: 10.1016/j.yebeh.2010.01.005. 45. Kluger G., Glauser T., Krauss G. et al. Adjunctive rufinamide in Lennox–Gastaut syndrome: a long-term, open-label ext
(check this in PDF content)
19
DOI: 10.1111/j.1600-0404.2010.01334.x. 46. Kluger G., Bauer B. Role of rufinamide in the management of Lennox–Gastaut syndrome (childhood epileptic encephalopathy). Neurop
(check this in PDF content)
20
PMID: 26537434.
(check this in PDF content)
21
DOI: 10.1111/epi.13222. 48. Lee E.H., Yum M.S., Choi H.W., Ko T.S. Long-term use of clobazam in Lennox– Gastaut syndrome: experience in a single tertiary epile
(check this in PDF content)
22
DOI: 10.1097/WNF.0b013e3182770730. 49. Lee E.H., Yum M.S., Ko T.S. Effectiveness and tolerability of rufinamide in child
(check this in PDF content)
23
Clin Neurol Neurosurg 2013;115(7):926–9.
(check this in PDF content)
24
PMID: 23083943. DOI: 10.1016/j.clineuro.2012.09.021. 50. Liao W.P., Shi Y.W., Long Y.S. et al. Partial epilepsy with antecedent febrile seizures and seizure aggravation by antiepileptic drugs: ass
(check this in PDF content)
25
DOI: 10.1111/j.1528-1167.2010.02645.x. 51. McMurray R., Striano P. Treatment of adults with Lennox–Gastaut syndrome: further analysis of efficacy and safety/ tolerability of r
(check this in PDF content)
26
DOI: 10.1007/s40120-016-0041-9. 52. Montouris G.D., Wheless J.W., Glauser T.A. The efficacy and tolerability of pharmacologic treatment options for Lennox– Gastaut syn
(check this in PDF content)
27
DOI: 10.1111/epi.12732. 53. Motte J., Trevathan E., Arvidsson J.F. et al. Lamotrigine for generalized seizures associated with the Lennox–Gastaut syndrome. N Engl J Med
(check this in PDF content)
28
DOI: 10.1056/NEJM199712183372504. 54. Mourand I., Crespel A., Gelisse P. Dramatic weight loss with rufinamide. Epilepsia 2013;54(1):e5–8. PMID: 227
(check this in PDF content)
29
DOI: 10.1111/j.1528-1167.2012.03579.x. 55. Ng Y.T., Conry J.A., Drummond R. et al. Randomized, phase III study results of clobazam in Lennox–Gastaut syndrome. Neurology 2011;77(15):1473–81.
(check this in PDF content)
30
PMID: 21956725. DOI: 10.1212/
(check this in PDF content)
31
WNL.0b013e318232de76. 56. Oguni H., Uehara T., Tanaka T. et al. Dramatic effect of ethosuximide on epileptic negative myoclonus: implications for the neurophysiological mechanism.
(check this in PDF content)
32
DOI: 10.1055/s-2007-973530. 57. Ohtsuka Y., Yoshinaga H., Shirasaka Y. et al. Long-term safety and seizure outcome in Japanese patients with Lennox– Gasta
(check this in PDF content)
33
DOI: 10.1016/j.eplepsyres.2016.01.002. 58. Ohtsuka Y., Yoshinaga H., Shirasaka Y. et al. Rufinamide as an adjunctive therapy for Lennox–Gastaut syndrome: a
(check this in PDF content)
34
PMID: 25219353. DOI: 10.1016/j. eplepsyres.2014.08.019. 59. Ostendorf A.P., Ng Y.T. Treatmentresistant Lennox–Gastaut syndrome: therapeutic trends, challenges and future directions. Neurops
(check this in PDF content)
35
DOI: 10.2147/NDT.S115996. 60. Palhagen S., Canger R., Henriksen O. et al. Rufinamide: a double-blind, placebo-controlled proof of
(check this in PDF content)
36
Practice Parameter Guidelines. 2nd edn. London: Springer, 2010. 578 p. 62. Panayotopoulos С.P. Principles of therapy in the epilepsies. In: A clinical guide to epileptic syndromes and their tre
(check this in PDF content)
37
DOI: 10.1212/WNL.52.9.1882. 64. Sankar R., Chung S., Perry M.S. et al. Clinical considerations in transitioning patients with epilepsy from clonazepam to clobaza
(check this in PDF content)
38
DOI: 10.1186/1752-1947-8-429. 65. Snead O.C., Hosey L.C. Treatment of epileptic falling spells with ethosuximide. Brain Dev 1987;9(6): 602–4. PMID: 3445921. 66
(check this in PDF content)
39
Gastaut Syndrome. Efficacy of felbamate in childhood epileptic encephalopathy (Lennox–Gastaut syndrome). N Engl J Med 1993;328(1):29–33. DOI: 10.1056/
(check this in PDF content)
40
NEJM199301073280105. 67. Thome-Souza S., Kadish N.E., Ramgopal S. et al. Safety and retention rate of rufinamide in 300 patients: a single pediatric epilepsy center exp
(check this in PDF content)
41
DOI: 10.1111/epi.12689. 68. Tomson T., Marson A., Boon P. et al. Valproate in the treatment of epilepsy in girls and women of childbearing potential. Epilepsi
(check this in PDF content)
42
DOI: 10.1016/j. pediatrneurol.2010.12.005. 70. Verrotti A., Loiacono G., Rossi A. et al. Successful treatment of refractory seizures with rufinamide in ch
(check this in PDF content)
43
DOI: 10.1177/0883073814542951. 71. Wheless J.W., Clarke D.F., Arzimanoglou A., Carpenter D.
(check this in PDF content)
44
Epileptic Disord 2007;9(4):353–412.
(check this in PDF content)
45
PMID: 18077226. DOI: 10.1684/ epd.2007.0144. 72. Wheless J.W., Clarke D.F., Carpenter D. Treatment of pediatric epilepsy: expert opinion, 2005. J Child Neurol 2005;20(Suppl 1):S1–56.
(check this in PDF content)
46
PMID: 16615562.
(check this in PDF content)
47
DOI: 10.1177/088307380502000101. 73. Wheless J. W., Conry J., Krauss G. et al. Safety and tolerability of rufinamide in children with epilepsy: a pooled analysis of 7 clinical studi
(check this in PDF content)
48
DOI: 10.1177/0883073809350508. 74. Wier H.A., Cerna A., So T.Y. Rufinamide for pediatric patients with Lennox– Gastaut syndrome: a comprehensive ove
(check this in PDF content)
49
PMID: 21351809.
(check this in PDF content)
50
DOI: 10.2165/11586920-00000000000000. Конфликт интересов. Авторы заявляют об отсутствии конфликта интересов. Conflict of interest. The authors declare no conflict of interest.
(check this in PDF content)